期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021; 70 (10)
A correction to this paper has been published: http://fcb4e4bc18db4e2ead7856820ff3646c.ebe14e7a.libvpn.zuel.edu.cn/10.1007/s00262-021-02929-0
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Tumor mutation burden (TMB) predicts response to immunotherapy in non-small cell lung cancer (NSCLC). The current TMB evaluation is expensive and not ......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Background T cell with chimeric antigen receptors (CAR-T) has presented remarkable efficacy for blood cancer as an emerging immunotherapy. However, fo......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Background This study evaluated the efficacy and safety of anlotinib combined with programmed cell death protein 1 (PD-1) blockade for the treatment o......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Purpose This study was designed to investigate the correlation between immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs) an......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Standard treatment regimen of gliomas has almost reached a bottleneck in terms of survival benefit. Immunotherapy has been explored and applied in gli......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Glioma stem cells (GSCs) contribute to the malignant growth of glioma, but little is known about the interaction between GSCs and tumor microenvironme......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
The expression status of programmed cell death-ligand 1/programmed cell death 1 (PD-L1/PD-1) and the infiltration of CD8(+) T cells in tumor tissues a......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Immune checkpoint blockade (ICB) of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint pathway has led to unpre......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
CD133 + cancer stem cells mediate chemoresistance in multiple aggressive cancers, and anti-CD133 chimeric antigen receptor T (CAR-T) cells are designe......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
TIGIT is a lymphocyte surface receptor, which is mainly expressed on the surface of CD8(+)T cells. The role of TIGIT in colorectal cancer and its expr......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Background Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), causes high mortality around the world. Previous studies have ......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
Objective Chemoradiotherapy (CRT) is the standard treatment for limited-stage small cell lung cancer (LS-SCLC), which can exert anti-tumor effects by ......
期刊： CANCER IMMUNOLOGY IMMUNOTHERAPY, ; ()
This work investigated the clinical prognostic implications and biological function of plasma soluble programmed cell death ligand 1 in breast cancer ......
